Clinical, epidemiological and taxonomic aspects of systemic candidiasis in an intensive care unit;Perfil clínico-epidemiológico y taxonómico de la candidiasis sistémica en una unidad de cuidados intensivos

Medicina Intensiva

Volumn 33, Issue 3, 2009, Pages 144-147

  Hernandez Sierra B ^a   Prieto Palomino, M Á ^a   Curiel Balsera, E ^a   Munoz Bono J ^a   Quesada Garcia G ^a   Arias Verdu M D ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Candida; Candida albicans; Candidiasis; Fluconazole; Fungemia; Intensive care units

Indexed keywords

ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL ARTICLE; DRAIN; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTENSIVE CARE; LENGTH OF STAY; MALE; MORTALITY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SEVILLA SCORE;

CANDIDA; CANDIDIASIS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 65549107996     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/S0210-5691(09)70948-9     Document Type: Article

References (20)

1. Eggiman P., Garbino J., and Pittet D. Epidemiology of Candida species infections in critically ill in non-inmunosuppressed patients. Lancet Infect Dis 3 (2003) 685-702
2. Vincent J.L., Anaissie E., and Buining H. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patient under intensive care. Intensive Care Med 24 (1998) 206-216
3. Ostrosky-Zeichner L.G., and Pappas P. Invasive candidiasis in the intensive care unit. Crit Care Med 34 (2006) 857-863
4. Peres-Bota D., Rodríguez-Villalobos H., Dimopoulos G., Melot C., and Vincent J.L. Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbiol Infect 10 (2004) 550-555
5. Charles P.E., Doise J.M., Quenot J.P., Haube H., Dalle P., Chavanet P., et al. Candidemia in critically ill patients: Difference of outcome between medical and surgical patients. Intensive Care Med 29 (2003) 2162-2169
6. Nollas Salas J., Rodríguez A., Olaechea P.M., Prieto J., and Almirante B. Epidemiología de la infección fúngica en el paciente crítico no granulocitopénico. Recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico. Med Intensiva 3 (2005) 4-11
7. Cuenca Estrella M., Martín Mazuelos E., Álvarez Lerma F., Ortiz Leyba C., and León Gil C. Infecciones por Candida spp. en el paciente crítico. Recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico. Med Intensiva 3 (2005) 12-20
8. Garnacho Montero J., León Gil C., Almirante B., Álvarez Lerma F., Cuenca Estrella M., García Rodríguez J.A., et al. Recomendaciones terapéuticas en el paciente crítico no neutropénico. Med Intensiva 3 (2005) 43-52
9. Cuétara M.S., Alambra A., and Del Palacio A. Diagnóstico microbiológico tradicional de la candidiasis invasora en el paciente crítico no neutropénico. Rev Iberoam Micol 23 (2006) 4-7
10. Duncan M.K., Pranab K.M., Thomas A.C., Pujol C., and Chandra J. Candida parapsilosis: characterization in an Outbreak Setting. Emerg Infect Dis 10 (2004) 1074-1081
11. Pemán J., Cantón E., Gobernado M., and The Spanish ECMM Working Group on Candidemia. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 24 (2005) 23-30
12. Blumberg H.M., Jarvis W.R., and Soucie J.M. Risk factors for candida bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33 (2001) 177-186
13. Colombo A.L., Perfecrt J., DiNubile M., Bartizal K., Motyl M., Hicks P., et al. Global distribution and outcomes for Candida species in invasive candidiasis; results from an international randomized double-blind study of caspofungina versus anfhotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Dis 22 (2003) 470-474
14. Cuenca-Estrella M., Díaz Guerra T., Mellado E., Monzón A., and Rodríguez-Tudela J.L. In vitro susceptibilities of bloobstream isolates of candida species to six antifungal agent; results from a population-based active surveillance program. Barcelona, Spain, 2002-2003. J Antimicrob Chemother 55 (2005) 194-199
15. Pfaller M.A., Diekkema D.J., Jones R., Sader H., Fluit A.C., Hollis R.J., and The SENTRY participant group. International surveillance of bloodstream infections due to Candida species; frecuency of occurrence and in vitro susceptibilities to fluonazol, ravuconazol and voriconazol of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39 (2001) 3254-3259
16. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
17. Miller L.G., Hajjeh R.A., and Edwards Jr. J.E. Estimating the cost of nosocomial candidemia in the United States. Clin Infect Dis 32 (2001) 1110-1116
18. Almirante B., Rodríguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al., The Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from populationbased surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43 (2005) 1829-1835
19. Nucci M., and Colombo A.L. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 21 (2002) 209-211
20. Weinberger M., Leibovici L., Perez S., Samra Z., Ostfeld I., Levi I., et al. Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 61 (2005) 146-154